Celyad Oncology SA (CLYYF)
USD 0.53
(-22.44%)
USD 0.53
(-22.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.49 Million EUR | -58.1% |
| 2022 | 20.26 Million EUR | -24.7% |
| 2021 | 26.9 Million EUR | 2.53% |
| 2020 | 26.24 Million EUR | -10.67% |
| 2019 | 29.37 Million EUR | -28.84% |
| 2018 | 41.28 Million EUR | 39.34% |
| 2017 | 29.62 Million EUR | -13.06% |
| 2016 | 34.07 Million EUR | 14.84% |
| 2015 | 29.67 Million EUR | 48.99% |
| 2014 | 19.91 Million EUR | 79.79% |
| 2013 | 11.07 Million EUR | 313.53% |
| 2012 | -5.18 Million EUR | -256.67% |
| 2011 | 3.31 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.08 Million EUR | 0.0% |
| 2023 Q2 | 5.42 Million EUR | 0.0% |
| 2023 Q4 | 4.74 Million EUR | 0.0% |
| 2022 Q4 | 12.01 Million EUR | 0.0% |
| 2022 Q2 | 7.64 Million EUR | 2.04% |
| 2022 Q1 | 7.49 Million EUR | -4.0% |
| 2022 FY | 20.26 Million EUR | -24.7% |
| 2021 Q4 | 7.8 Million EUR | 26.13% |
| 2021 Q2 | 6.36 Million EUR | -2.96% |
| 2021 Q3 | 6.18 Million EUR | -2.72% |
| 2021 Q1 | 6.55 Million EUR | 1.2% |
| 2021 FY | 26.9 Million EUR | 2.53% |
| 2020 Q2 | 15.24 Million EUR | 0.0% |
| 2020 FY | 26.24 Million EUR | -10.67% |
| 2020 Q4 | 6.47 Million EUR | 12.51% |
| 2020 Q3 | 5.75 Million EUR | -62.24% |
| 2019 FY | 29.37 Million EUR | -14.85% |
| 2019 Q1 | -840.75 Thousand EUR | -104.32% |
| 2019 Q2 | 16.32 Million EUR | 2042.19% |
| 2019 Q4 | 16.3 Million EUR | 0.0% |
| 2018 Q2 | 21.3 Million EUR | 16335.43% |
| 2018 FY | 34.5 Million EUR | 15.7% |
| 2018 Q4 | 19.47 Million EUR | 0.0% |
| 2018 Q1 | -131.25 Thousand EUR | -100.3% |
| 2017 FY | 29.82 Million EUR | -14.12% |
| 2017 Q4 | 43.54 Million EUR | 0.0% |
| 2017 Q2 | 16.66 Million EUR | 5497.25% |
| 2017 Q1 | -308.75 Thousand EUR | -101.94% |
| 2016 FY | 34.72 Million EUR | 16.63% |
| 2016 Q2 | 17.48 Million EUR | 2694.36% |
| 2016 Q4 | 15.89 Million EUR | 0.0% |
| 2016 Q1 | -674 Thousand EUR | -104.85% |
| 2015 Q4 | 13.88 Million EUR | 25118.02% |
| 2015 FY | 29.77 Million EUR | 49.48% |
| 2015 Q3 | -55.5 Thousand EUR | -100.36% |
| 2015 Q2 | 15.48 Million EUR | 27997.3% |
| 2015 Q1 | -55.5 Thousand EUR | -100.54% |
| 2014 FY | 19.91 Million EUR | 79.79% |
| 2014 Q1 | -240.75 Thousand EUR | -102.13% |
| 2014 Q4 | 10.3 Million EUR | 4382.04% |
| 2014 Q2 | 6.43 Million EUR | 2770.82% |
| 2014 Q3 | -240.75 Thousand EUR | -103.74% |
| 2013 Q1 | 1.48 Million EUR | 0.0% |
| 2013 Q2 | 2.82 Million EUR | 90.5% |
| 2013 Q3 | 1.48 Million EUR | -47.51% |
| 2013 Q4 | 11.28 Million EUR | 660.84% |
| 2013 FY | 11.07 Million EUR | 313.53% |
| 2012 Q3 | -2.69 Million EUR | 0.0% |
| 2012 Q2 | -2.69 Million EUR | 0.0% |
| 2012 Q1 | -2.69 Million EUR | 0.0% |
| 2012 FY | -5.18 Million EUR | -256.67% |
| 2012 Q4 | 1.48 Million EUR | 155.02% |
| 2011 Q1 | -561.96 Thousand EUR | 0.0% |
| 2011 Q2 | -561.96 Thousand EUR | 0.0% |
| 2011 Q3 | -561.96 Thousand EUR | 0.0% |
| 2011 Q4 | -2.69 Million EUR | -379.69% |
| 2011 FY | 3.31 Million EUR | 0.0% |
| 2010 Q4 | -561.96 Thousand EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | 21.874% |
| Skye Bioscience, Inc. | 13.54 Million USD | 37.332% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 77.212% |
| Nascent Biotech, Inc. | 2.22 Million USD | -280.738% |
| Qrons Inc. | 643.67 Thousand USD | -1218.985% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1943.425% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -68.384% |
| BioStem Technologies, Inc. | 22.97 Million USD | 63.046% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -819.319% |
| CSL Limited | 3.44 Billion USD | 99.754% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 85.219% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 71.272% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1178.614% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -535.75% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2079.348% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 46.971% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 90.217% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -72.634% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -3143.85% |
| SQZ Biotechnologies Company | 85.61 Million USD | 90.084% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -191.129% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -465.284% |
| Mesoblast Limited | 5.9 Million USD | -43.85% |
| Marizyme, Inc. | 19.23 Million USD | 55.873% |
| Genus plc | 147.7 Million USD | 94.252% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 3.295% |
| Pharming Group N.V. | 225.49 Million USD | 96.235% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -314.408% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -532.852% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1.811% |
| ContraFect Corporation | 56.88 Million USD | 85.076% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -92.575% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -474.133% |
| IMV Inc. | 37.7 Million USD | 77.486% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -204.262% |
| MultiCell Technologies, Inc. | 567.42 USD | -1496146.167% |
| ONE Bio Corp. | 6.44 Million USD | -31.753% |
| Accustem Sciences Inc. | 3.74 Million USD | -126.616% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 90.122% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1495.979% |
| Q BioMed Inc. | 3.43 Million USD | -147.044% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 65.648% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -223.118% |
| Biomind Labs Inc. | 994.18 Thousand USD | -753.968% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 91.453% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -382.475% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -26.377% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -355.382% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 34060.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -362.646% |
| GB Sciences, Inc. | 1.42 Million USD | -497.673% |
| Alpha Cognition Inc. | 9.7 Million USD | 12.525% |
| HST Global, Inc. | 140.9 Thousand USD | -5925.251% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -654.727% |
| Halberd Corporation | 74.84 Thousand USD | -11243.898% |
| Enzolytics Inc. | 2.17 Million USD | -289.538% |
| Agentix Corp. | 1.37 Million USD | -518.915% |
| Resverlogix Corp. | 12.71 Million USD | 33.213% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -132.558% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.446% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -713.218% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -253.024% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -437.561% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -149.341% |
| AVAX Technologies, Inc. | 7.31 Million USD | -16.138% |
| Zenith Capital Corp. | 8.94 Million USD | 5.065% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.971% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -48634.286% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -245.78% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -4850.178% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -341.979% |
| Kadimastem Ltd | 2.41 Million USD | -252.266% |
| Helix BioMedix, Inc. | 1.97 Million USD | -330.52% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -4578.073% |
| LadRx Corporation | 3.81 Million USD | -122.73% |
| Cell Source, Inc. | 4.32 Million USD | -96.285% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -819.319% |
| NovAccess Global Inc. | 2.46 Million USD | -244.176% |
| Affymax, Inc. | 39.38 Million USD | 78.444% |
| Itoco Inc. | 919.14 Thousand USD | -823.687% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -100.311% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -658.713% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1430.982% |
| CytoDyn Inc. | 18.05 Million USD | 52.985% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -33631.972% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3757.723% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -497.975% |
| SYBLEU INC | 160.87 Thousand USD | -5177.356% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -367.429% |
| International Stem Cell Corporation | 5.27 Million USD | -61.07% |
| Bioxytran, Inc. | 3.82 Million USD | -122.243% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -16027.807% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -41634.257% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 76.59% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -424.722% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1053.791% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -172.903% |
| Neutra Corp. | 243.82 Thousand USD | -3382.063% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 51.366% |
| PureTech Health plc | 144.59 Million USD | 94.129% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 58.565% |
| IXICO plc | 4.7 Million USD | -80.37% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 3.49% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 92.79% |
| CSL Limited | 3.89 Billion USD | 99.782% |
| Cellectis S.A. | 97.32 Million USD | 91.276% |